NASDAQ$XWEL
XpresSpa Group Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported second quarter results, demonstrating progress on strategic imperatives and securing a significant CDC biosurveillance contract.
XpresSpa Group reported a revenue increase to $13.6 million compared to $9.1 million in the corresponding period in 2021. The company's net loss attributable to common shareholders was $7.9 million, compared to $4.5 million in the prior year second quarter. XpresCheck was awarded a new CDC contract valued up to $61 million.
- XpresCheck awarded new CDC biosurveillance contract valued up to $61 million.
- 26 spas currently open globally with another five scheduled to open in the third quarter of this year, including first location in Turkey’s Istanbul Airport.
- New retail strategy to drive more foot traffic into airport locations and online platform.
- Planning to refresh the look and appearance of Spa locations later this year and extending into 2023, and also plan to open third Treat location in Salt Lake City, Utah in late Q3.
Headline financials
Revenue & EPS history
XpresSpa · Revenue · Quarterly
$13.6M
Revenue by segment
XpresSpa · $6.64M total across 3 segments · Q1 2026
- XpresSpa$4.2M—63.2%
- XpresTest$1.92M—28.9%
- Naples Wax$524K—7.9%
Forward guidance
XpresSpa Group is focused on creating a strong retail engine, optimizing capital, and managing sustainable growth. They are planning to refresh Spa locations and open a new Treat location in Salt Lake City.
Tailwinds
- Strong retail engine creation.
- Capital optimization.
- Sustainable growth management.
- Refreshing Spa locations look.
- Opening new Treat location in Salt Lake City.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
+1.1%
Avg return
Earnings day
-2.3%
Avg return
5 days after
-4.5%
Avg return
30 days after
43%
16 / 37 earnings
Positive
+24.4%
Q4 2019
Best reaction
-11.1%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | — | — | — | |
| Q3 2025 | +0.0% | -8.4% | -9.6% | |
| Q2 2025 | -5.8% | -8.3% | -8.3% | |
| Q1 2025 | +1.2% | +12.8% | +9.3% | |
| Q4 2024 | +0.0% | +0.0% | +15.4% | |
| Q3 2024 | -1.2% | -10.6% | -24.1% | |
| Q2 2024 | +3.7% | +0.5% | -14.8% | |
| Q1 2024 | +3.4% | -8.4% | +41.6% | |
| Q4 2023 | +0.0% | +0.7% | +32.1% | |
| Q3 2023 | +6.2% | +35.4% | +31.1% | |
| Q2 2023 | -4.2% | -4.2% | -25.0% | |
| Q1 2023 | +0.0% | +4.2% | +4.2% | |
| Q4 2022 | +6.3% | -9.4% | -21.9% | |
| Q3 2022 | +0.0% | -12.3% | -10.5% | |
| Q2 2022 | -6.5% | -5.4% | +9.7% | |
| Q1 2022 | -1.1% | -18.7% | -22.0% | |
| Q4 2021 | +8.2% | +52.0% | +11.2% | |
| Q3 2021 | +11.7% | +13.1% | +25.5% | |
| Q2 2021 | -6.9% | -13.1% | -2.9% | |
| Q4 2020 | +6.4% | -3.5% | -20.8% | |
| Q3 2020 | -1.1% | -13.4% | -22.5% | |
| Q2 2020 | -6.5% | -4.2% | -42.9% | |
| Q1 2020 | -7.5% | -5.5% | +6.5% | |
| Q4 2019 | +24.4% | +26.8% | +17.1% | |
| Q3 2019 | +2.0% | -5.9% | -41.6% | |
| Q2 2019 | +0.0% | +21.2% | +31.9% | |
| Q1 2019 | +7.8% | -9.0% | -40.0% | |
| Q4 2018 | +0.3% | -12.0% | -22.7% | |
| Q3 2018 | +0.0% | +0.0% | +11.1% | |
| Q2 2018 | +0.0% | -25.0% | -20.0% | |
| Q1 2018 | -4.8% | -31.7% | -20.6% | |
| Q4 2017 | -11.1% | -24.7% | -17.3% | |
| Q3 2017 | -0.8% | -4.0% | -6.5% | |
| Q2 2017 | +11.5% | +4.4% | +9.7% | |
| Q1 2017 | +4.9% | +1.9% | +5.6% | |
| Q4 2016 | +0.9% | -9.7% | -20.8% | |
| Q3 2016 | +0.8% | -8.0% | -15.6% | |
| Q2 2016 | -1.9% | -1.0% | +1.9% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro